section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: epistaxis, nasal irritation, nasal stuffiness, rhinorrhea, sneezing, tearing eyes

Endo: adrenal suppression (increased dose, long-term therapy only), growth (children)

GI: nausea

Neuro: dizziness, headache

Interactions

Drug-drug:

Availability

Route/Dosage

US Brand Names

Beconase AQ, QNASL

Action

  • Potent, locally acting anti-inflammatory and immune modifier.
Therapeutic effects:
  • Decrease in symptoms of allergic or nonallergic rhinitis.

Classifications

Therapeutic Classification: corticosteroids

Pharmacologic Classification: corticosteroids

Pharmacokinetics

Absorption: 27–44% absorbed following intranasal administration; action is primarily local following intranasal use.

Distribution: Crosses the placenta and enters breast milk in small amounts.

Metabolism/Excretion: Primarily converted to beclomethasone 17-monopropionate (active metabolite); 60% excreted in feces, 12% in urine.

Half-Life: 2.7 hr.

Canadian Brand Names

Rivanase AQ

Time/Action Profile

(improvement in symptoms)

ROUTEONSETPEAKDURATION
Intranasal1–3 daysup to 2 wkunknown

Up to 2 wk in some patients.

Patient/Family Teaching

Pronunciation

be-kloe-METH-a-sone